Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s share price hit a new 52-week high on Thursday . The stock traded as high as $15.24 and last traded at $14.23, with a volume of 3,493,447 shares changing hands. The stock had previously closed at $11.75.

Several equities analysts have weighed in on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Sunday, May 29th. Brean Capital reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, June 6th. JMP Securities boosted their target price on shares of Vanda Pharmaceuticals from $18.00 to $22.00 and gave the stock a “market outperform” rating in a report on Friday. Piper Jaffray Cos. reissued a “buy” rating and issued a $16.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, July 28th. Finally, Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Vanda Pharmaceuticals has an average rating of “Buy” and an average price target of $17.50.

The firm has a 50 day moving average of $12.00 and a 200 day moving average of $9.86. The firm’s market cap is $663.54 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.12. The business earned $36.02 million during the quarter, compared to analyst estimates of $36.03 million. Vanda Pharmaceuticals’s quarterly revenue was up 30.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.13) EPS. On average, equities analysts forecast that Vanda Pharmaceuticals Inc. will post ($0.61) EPS for the current fiscal year.

A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. Bank of Montreal Can raised its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 23.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,208,918 shares of the biopharmaceutical company’s stock after buying an additional 228,074 shares during the period. Bank of Montreal Can owned approximately 2.82% of Vanda Pharmaceuticals worth $11,255,000 as of its most recent filing with the SEC.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.